Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2013 | 03-2013 | 12-2012 | 12-2011 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | N/A | N/A | 4,158 | 29,690 |
| Other current assets | 0 | 0 | 1,247 | 420 |
| TOTAL | $N/A | $N/A | $5,405 | $30,110 |
| Non-Current Assets | ||||
| PPE Net | N/A | N/A | 13,335 | 13,040 |
| Other Non-Current Assets | 0 | 0 | 1,030 | 0 |
| TOTAL | $N/A | $N/A | $14,365 | $13,040 |
| Total Assets | $N/A | $N/A | $13,423 | $39,920 |
| Liabilities | ||||
| Current Liabilities | ||||
| Short Term Debt | N/A | N/A | 94,500 | 0 |
| Accounts payable and accrued liabilities | 0 | 0 | 1,800 | 0 |
| Accrued Expenses | N/A | N/A | 6,000 | 0 |
| Other current liabilities | N/A | N/A | 14,680 | 0 |
| TOTAL | $N/A | $N/A | $117,935 | $8,850 |
| Non-Current Liabilities | ||||
| Long Term Debt | N/A | N/A | 10,995 | 18,430 |
| Other Non-Current Liabilities | 0 | 0 | 2,731 | 470 |
| TOTAL | $N/A | $N/A | $16,771 | $18,900 |
| Total Liabilities | $N/A | $N/A | $134,717 | $99,970 |
| Shareholders' Equity | ||||
| Retained earnings | N/A | N/A | -218,326 | -160,060 |
| Other shareholders' equity | 0 | 0 | 95,442 | 100,020 |
| TOTAL | $N/A | $N/A | $-121,294 | $-60,040 |
| Total Liabilities And Equity | $0 | $0 | $13,423 | $39,930 |